These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38994712)

  • 1. Type 2 severe asthma: pathophysiology and treatment with biologics.
    Pelaia C; Melhorn J; Hinks TS; Couillard S; Vatrella A; Pelaia G; Pavord ID
    Expert Rev Respir Med; 2024 Jul; 18(7):485-498. PubMed ID: 38994712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in biologic therapy in eosinophilic asthma.
    Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
    Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
    Krings JG; McGregor MC; Bacharier LB; Castro M
    J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type-2 severe asthma comorbidities in the era of biologics: time to rethink clinical response?
    Portacci A; Dragonieri S; Carpagnano GE
    Expert Rev Respir Med; 2024 May; 18(5):249-253. PubMed ID: 38845590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of biologics in personalized asthma care.
    Watchorn D; Holguin F
    Expert Rev Clin Immunol; 2021 Dec; 17(12):1301-1309. PubMed ID: 34767743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe T2-high asthma in the biologics era: European experts' opinion.
    Pavord I; Bahmer T; Braido F; Cosío BG; Humbert M; Idzko M; Adamek L
    Eur Respir Rev; 2019 Jun; 28(152):. PubMed ID: 31285291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.
    Marone G; Spadaro G; Braile M; Poto R; Criscuolo G; Pahima H; Loffredo S; Levi-Schaffer F; Varricchi G
    Expert Opin Investig Drugs; 2019 Nov; 28(11):931-940. PubMed ID: 31549891
    [No Abstract]   [Full Text] [Related]  

  • 14. Precision medicine in asthma: linking phenotypes to targeted treatments.
    Chung KF
    Curr Opin Pulm Med; 2018 Jan; 24(1):4-10. PubMed ID: 29036018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma.
    Al Meslamani AZ
    Expert Opin Biol Ther; 2024; 24(1-2):25-29. PubMed ID: 38174421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
    Kepil Özdemir S; Bavbek S
    Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment.
    Bagnasco D; Heffler E; Testino E; Passalacqua G; Canonica GW
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):113-120. PubMed ID: 30632416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
    Santus P; Saad M; Damiani G; Patella V; Radovanovic D
    Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.